Khizar Rana, Mark Beecher, Jessica Y Tong, Tejaswi Bommireddy, Katja Ullrich, Richard Hart, Jwu Jin Khong, Geoffrey Wilcsek, Thomas Hardy, Phung Vu, Dinesh Selva
{"title":"眼眶鳞状细胞癌的免疫治疗。","authors":"Khizar Rana, Mark Beecher, Jessica Y Tong, Tejaswi Bommireddy, Katja Ullrich, Richard Hart, Jwu Jin Khong, Geoffrey Wilcsek, Thomas Hardy, Phung Vu, Dinesh Selva","doi":"10.1080/01676830.2025.2469305","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the demographics, clinical features and response of orbital squamous cell carcinoma treated with immunotherapy in an Australian and New Zealand cohort.</p><p><strong>Methods: </strong>This is a multi-institutional, retrospective case series. Data was collected on patient demographics, clinical presentation, imaging findings, treatment course and outcomes. Details of post-immunotherapy surgical interventions were documented along with their histological findings.</p><p><strong>Results: </strong>Ten patients were included. All patients had invasive orbital squamous cell carcinoma. Perineural spread was present in six patients. Seven patients received Cemiplimab, while three patients received Pembrolizumab. No patients experienced side effects requiring cessation of immunotherapy. One patient died during follow up due to an unrelated cause. Eight (80%) patients had measurable radiological response, whereas one (10%) patient had progressive disease. Two patients had orbital exenteration: one due to progressive disease and one due to residual disease on MRI. One patient had orbital mapping biopsies. Two (66%) patients that had tissue analysis following immunotherapy showed complete pathologic response.</p><p><strong>Conclusion: </strong>Our findings support the emerging role of immunotherapy in the management of invasive orbital squamous cell carcinoma.</p>","PeriodicalId":47421,"journal":{"name":"Orbit-The International Journal on Orbital Disorders-Oculoplastic and Lacrimal Surgery","volume":" ","pages":"1-7"},"PeriodicalIF":0.9000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy for orbital squamous cell carcinoma.\",\"authors\":\"Khizar Rana, Mark Beecher, Jessica Y Tong, Tejaswi Bommireddy, Katja Ullrich, Richard Hart, Jwu Jin Khong, Geoffrey Wilcsek, Thomas Hardy, Phung Vu, Dinesh Selva\",\"doi\":\"10.1080/01676830.2025.2469305\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the demographics, clinical features and response of orbital squamous cell carcinoma treated with immunotherapy in an Australian and New Zealand cohort.</p><p><strong>Methods: </strong>This is a multi-institutional, retrospective case series. Data was collected on patient demographics, clinical presentation, imaging findings, treatment course and outcomes. Details of post-immunotherapy surgical interventions were documented along with their histological findings.</p><p><strong>Results: </strong>Ten patients were included. All patients had invasive orbital squamous cell carcinoma. Perineural spread was present in six patients. Seven patients received Cemiplimab, while three patients received Pembrolizumab. No patients experienced side effects requiring cessation of immunotherapy. One patient died during follow up due to an unrelated cause. Eight (80%) patients had measurable radiological response, whereas one (10%) patient had progressive disease. Two patients had orbital exenteration: one due to progressive disease and one due to residual disease on MRI. One patient had orbital mapping biopsies. Two (66%) patients that had tissue analysis following immunotherapy showed complete pathologic response.</p><p><strong>Conclusion: </strong>Our findings support the emerging role of immunotherapy in the management of invasive orbital squamous cell carcinoma.</p>\",\"PeriodicalId\":47421,\"journal\":{\"name\":\"Orbit-The International Journal on Orbital Disorders-Oculoplastic and Lacrimal Surgery\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Orbit-The International Journal on Orbital Disorders-Oculoplastic and Lacrimal Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/01676830.2025.2469305\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orbit-The International Journal on Orbital Disorders-Oculoplastic and Lacrimal Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/01676830.2025.2469305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Immunotherapy for orbital squamous cell carcinoma.
Purpose: To evaluate the demographics, clinical features and response of orbital squamous cell carcinoma treated with immunotherapy in an Australian and New Zealand cohort.
Methods: This is a multi-institutional, retrospective case series. Data was collected on patient demographics, clinical presentation, imaging findings, treatment course and outcomes. Details of post-immunotherapy surgical interventions were documented along with their histological findings.
Results: Ten patients were included. All patients had invasive orbital squamous cell carcinoma. Perineural spread was present in six patients. Seven patients received Cemiplimab, while three patients received Pembrolizumab. No patients experienced side effects requiring cessation of immunotherapy. One patient died during follow up due to an unrelated cause. Eight (80%) patients had measurable radiological response, whereas one (10%) patient had progressive disease. Two patients had orbital exenteration: one due to progressive disease and one due to residual disease on MRI. One patient had orbital mapping biopsies. Two (66%) patients that had tissue analysis following immunotherapy showed complete pathologic response.
Conclusion: Our findings support the emerging role of immunotherapy in the management of invasive orbital squamous cell carcinoma.
期刊介绍：
Orbit is the international medium covering developments and results from the variety of medical disciplines that overlap and converge in the field of orbital disorders: ophthalmology, otolaryngology, reconstructive and maxillofacial surgery, medicine and endocrinology, radiology, radiotherapy and oncology, neurology, neuroophthalmology and neurosurgery, pathology and immunology, haematology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
